1.7800
07-January-25 15:45:00
15 minutes delayed
Stocks
-0.1200
-6.32%
Today's range
1.7200 - 1.9899
ISIN
N/A
Source
NASDAQ
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors
18 Sep 2024 07:30:00 By Nasdaq GlobeNewswire